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Introduction: Nanobiotechnology can provide the development of nanoparticles for diagnosis/treatment of 
human cancer. Aim of this work was to validate a silica nanoparticles (SNP)-based system functionalized with 
anti-Her2 antibody fragment and loaded with radioactive/fluorescent probes for detection of aggressive breast 
cancer. 
Methods: SNPs carrying (ETZ-2) or not (ETZ-1, control) the Her2 antibody fragment were used in in vitro binding 
kinetic in Her2 positive (SKBR-3) and negative (MDA-MB-468) breast cancer cell lines. In parallel, the same SNPs 
were derivatized with nitril-triacetic acid and reacted with His-Tag, previously labelled with 99mTc-Tricarbonyl 
complex. Labelled SNPs were used for different experiments: in vitro uptake kinetic in SKBR-3 and MDA-MB-
468 cells (20 min, 1 h, 4h and 24h); ex vivo distribution in tumour and peripheral organs in animals implanted 
with MDA-MB-468 or SKBR-3 cells, at 4h from ETZ-2 injection. SNPs binding in cells was expressed as 
percentage of the total radioactivity counted; uptake in tumours and tissues were calculated as percentage of 
injected dose per gram of tissue. Slices of tumour were also fixed with 4% PAF and observed by fluorescence. In 
parallel, additional animals bearing SKBR-3 or MDA-MB-468 lesions were treated with liposomal doxorubicin (3 
mg/kg in 40µl) or vehicle, and tumour uptake of [18F]FDG and [11C]Choline was evaluated ex vivo with double 
autoradiography.  
Results: ETZ-2 specifically binds SKBR-3 cells in vitro, reaching a maximum uptake ratio of 2,1 on MDA-MB-468 
cells after 4h. The same result was confirmed in tumours, after the biodistribution study and observation in 
fluorescence. Standard treatment particularly affected SKBR-3 lesions growth, in which we observed a 12,4% 
decrease of [18F]FDG and a 14.3% increase of [11C]Choline uptake, compared to control. Comparison with NPSs 
filled with doxorubicin are in progress. 
Conclusion: Labelled SNPs resulted a useful detection system for Her2 positive breast cancer and could be used 
for targeted therapy.  
